25th Oct 2022 13:46
Renalytix PLC - London-based diagnostics company focused on kidney health - Says US federal Medicare administrative contractor, National Government Services, starts paying for use of KidneyIntelX, a test that predicts which adult patients with type 2 diabetes and with chronic kidney disease are at risk from decline in kidney function. Renalytix will receive USD950 per reportable result. Medicare patient samples are being processed in the company's New York laboratory.
Current stock price: 49.70 pence, down 0.6% on Tuesday
12-month change: down 94%
By Chris Dorrell; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
Renalytix Plc